{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:08:29Z","timestamp":1791389309906,"version":"4.3.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001067","name":"Juvenile Diabetes Research Foundation Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000901","name":"Juvenile Diabetes Research Foundation International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000901","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite increasing knowledge about the factors involved in the progression of diabetic complications, diabetic kidney disease (DKD) continues to be a major health burden. Current therapies only slow but do not prevent the progression of DKD. Thus, there is an urgent need to develop novel therapy to halt the progression of DKD and improve disease prognosis. In our preclinical study where we administered a histone deacetylase (HDAC) inhibitor, valproic acid, to streptozotocin-induced diabetic mice, albuminuria and glomerulosclerosis were attenuated. Furthermore, we discovered that valproic acid attenuated diabetes-induced upregulation of complement C5a receptors, with a concomitant reduction in markers of cellular senescence and senescence-associated secretory phenotype. Interestingly, further examination of mice lacking the C5a receptor 1 (C5aR1) gene revealed that cellular senescence was attenuated in diabetes. Similar results were observed in diabetic mice treated with a C5aR1 inhibitor, PMX53. RNA-sequencing analyses showed that PMX53 significantly regulated genes associated with cell cycle pathways leading to cellular senescence. Collectively, these results for the first time demonstrated that complement C5a mediates cellular senescence in diabetic kidney disease. Cellular senescence has been implicated in the pathogenesis of diabetic kidney disease, thus therapies to inhibit cellular senescence such as complement inhibitors present as a novel therapeutic option to treat diabetic kidney disease.<\/jats:p>","DOI":"10.1038\/s41598-022-24851-w","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T07:04:22Z","timestamp":1669359862000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors"],"prefix":"10.1038","volume":"12","author":[{"given":"Melinda T.","family":"Coughlan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ziemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Laskowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trent M.","family":"Woodruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sih Min","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"24851_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 10th edn, https:\/\/www.diabetesatlas.org (2021)."},{"key":"24851_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1053\/j.ackd.2017.10.011","volume":"25","author":"DN Koye","year":"2018","unstructured":"Koye, D. N., Magliano, D. J., Nelson, R. G. & Pavkov, M. E. The global epidemiology of diabetes and kidney disease. Adv. Chronic Kidney Dis. 25, 121\u2013132. https:\/\/doi.org\/10.1053\/j.ackd.2017.10.011 (2018).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"24851_CR3","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/cjn.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic, R. Z., Rooney, M. T. & Tuttle, K. R. Diabetic kidney disease: Challenges, progress, and possibilities. Clin. J. Am. Soc. Nephrol. CJASN 12, 2032\u20132045. https:\/\/doi.org\/10.2215\/cjn.11491116 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"24851_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","volume":"17","author":"RA DeFronzo","year":"2021","unstructured":"DeFronzo, R. A., Reeves, W. B. & Awad, A. S. Pathophysiology of diabetic kidney disease: Impact of SGLT2 inhibitors. Nat. Rev. Nephrol. 17, 319\u2013334. https:\/\/doi.org\/10.1038\/s41581-021-00393-8 (2021).","journal-title":"Nat. Rev. Nephrol."},{"key":"24851_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12933-020-01163-9","volume":"19","author":"F Giorgino","year":"2020","unstructured":"Giorgino, F., Vora, J., Fenici, P. & Solini, A. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. Cardiovasc. Diabetol. 19, 196. https:\/\/doi.org\/10.1186\/s12933-020-01163-9 (2020).","journal-title":"Cardiovasc. Diabetol."},{"key":"24851_CR6","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.3390\/ijms19092630","volume":"19","author":"MJ Hadden","year":"2018","unstructured":"Hadden, M. J. & Advani, A. Histone deacetylase inhibitors and diabetic kidney disease. Int. J. Mol. Sci. 19, 2630. https:\/\/doi.org\/10.3390\/ijms19092630 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"24851_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.yexmp.2015.01.003","volume":"98","author":"S Khan","year":"2015","unstructured":"Khan, S., Jena, G. & Tikoo, K. Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat. Exp. Mol. Pathol. 98, 230\u2013239. https:\/\/doi.org\/10.1016\/j.yexmp.2015.01.003 (2015).","journal-title":"Exp. Mol. Pathol."},{"key":"24851_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3892\/mmr.2015.4580","volume":"13","author":"XY Sun","year":"2016","unstructured":"Sun, X. Y. et al. Valproate attenuates diabetic nephropathy through inhibition of endoplasmic reticulum stress-induced apoptosis. Mol. Med. Rep. 13, 661\u2013668. https:\/\/doi.org\/10.3892\/mmr.2015.4580 (2016).","journal-title":"Mol. Med. Rep."},{"key":"24851_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.645518","author":"MLS Mello","year":"2021","unstructured":"Mello, M. L. S. Sodium valproate-induced chromatin remodeling. Front. Cell Dev. Biol. https:\/\/doi.org\/10.3389\/fcell.2021.645518 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"24851_CR10","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1038\/s41598-021-81794-4","volume":"11","author":"MB Felisbino","year":"2021","unstructured":"Felisbino, M. B. et al. Valproic acid influences the expression of genes implicated with hyperglycaemia-induced complement and coagulation pathways. Sci. Rep. 11, 2163 (2021).","journal-title":"Sci. Rep."},{"key":"24851_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2337\/db19-0043","volume":"69","author":"SM Tan","year":"2020","unstructured":"Tan, S. M. et al. Complement C5a induces renal injury in diabetic kidney disease by disrupting mitochondrial metabolic agility. Diabetes 69, 83\u201398. https:\/\/doi.org\/10.2337\/db19-0043 (2020).","journal-title":"Diabetes"},{"key":"24851_CR12","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2021.0125","author":"SM Tan","year":"2021","unstructured":"Tan, S. M., Snelson, M., \u00d8stergaard, J. A. & Coughlan, M. T. The complement pathway: New insights into immunometabolic signalling in diabetic kidney disease. Antioxid. Redox Signal. https:\/\/doi.org\/10.1089\/ars.2021.0125 (2021).","journal-title":"Antioxid. Redox Signal."},{"key":"24851_CR13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.metabol.2015.01.014","volume":"64","author":"L Li","year":"2015","unstructured":"Li, L. et al. C3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt\/\u03b2-catenin signaling pathway in diabetic kidney disease. Metabolism 64, 597\u2013610. https:\/\/doi.org\/10.1016\/j.metabol.2015.01.014 (2015).","journal-title":"Metabolism"},{"key":"24851_CR14","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/ndt\/gfx336","volume":"33","author":"WH Yiu","year":"2018","unstructured":"Yiu, W. H. et al. Complement C5a inhibition moderates lipid metabolism and reduces tubulointerstitial fibrosis in diabetic nephropathy. Nephrol. Dial. Transplant. 33, 1323\u20131332. https:\/\/doi.org\/10.1093\/ndt\/gfx336 (2018).","journal-title":"Nephrol. Dial. Transplant."},{"key":"24851_CR15","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.18632\/aging.102059","volume":"11","author":"G Castellano","year":"2019","unstructured":"Castellano, G. et al. Complement component C5a induces aberrant epigenetic modifications in renal tubular epithelial cells accelerating senescence by Wnt4\/\u03b2catenin signaling after ischemia\/reperfusion injury. Aging (Albany NY) 11, 4382\u20134406 (2019).","journal-title":"Aging (Albany NY)"},{"key":"24851_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11892-020-01314-y","volume":"20","author":"CD Wiley","year":"2020","unstructured":"Wiley, C. D. Role of senescent renal cells in pathophysiology of diabetic kidney disease. Curr. Diab.Rep. 20, 33. https:\/\/doi.org\/10.1007\/s11892-020-01314-y (2020).","journal-title":"Curr. Diab.Rep."},{"key":"24851_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biochi.2014.12.015","volume":"110","author":"S Khan","year":"2015","unstructured":"Khan, S., Jena, G., Tikoo, K. & Kumar, V. Valproate attenuates the proteinuria, podocyte and renal injury by facilitating autophagy and inactivation of NF-\u03baB\/iNOS signaling in diabetic rat. Biochimie 110, 1\u201316. https:\/\/doi.org\/10.1016\/j.biochi.2014.12.015 (2015).","journal-title":"Biochimie"},{"key":"24851_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-4939-6670-7_3","volume":"1534","author":"M Shtutman","year":"2017","unstructured":"Shtutman, M., Chang, B. D., Schools, G. P. & Broude, E. V. Cellular model of p21-induced senescence. Methods Mol. Biol. 1534, 31\u201339. https:\/\/doi.org\/10.1007\/978-1-4939-6670-7_3 (2017).","journal-title":"Methods Mol. Biol."},{"key":"24851_CR19","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1016\/j.biocel.2009.04.005","volume":"41","author":"HD Manthey","year":"2009","unstructured":"Manthey, H. D., Woodruff, T. M., Taylor, S. M. & Monk, P. N. Complement component 5a (C5a). Int. J. Biochem. Cell Biol. 41, 2114\u20132117. https:\/\/doi.org\/10.1016\/j.biocel.2009.04.005 (2009).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"24851_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/biom10030420","author":"M Mijit","year":"2020","unstructured":"Mijit, M., Caracciolo, V., Melillo, A., Amicarelli, F. & Giordano, A. Role of p53 in the regulation of cellular senescence. Biomolecules https:\/\/doi.org\/10.3390\/biom10030420 (2020).","journal-title":"Biomolecules"},{"key":"24851_CR21","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1038\/onc.2012.640","volume":"32","author":"A Rufini","year":"2013","unstructured":"Rufini, A., Tucci, P., Celardo, I. & Melino, G. Senescence and aging: The critical roles of p53. Oncogene 32, 5129\u20135143. https:\/\/doi.org\/10.1038\/onc.2012.640 (2013).","journal-title":"Oncogene"},{"key":"24851_CR22","unstructured":"Rahman, M. & Nguyen, H. In StatPearls (StatPearls Publishing Copyright \u00a9 2022, StatPearls Publishing LLC., 2022)."},{"key":"24851_CR23","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/jbt.21807","volume":"30","author":"S Khan","year":"2016","unstructured":"Khan, S. & Jena, G. Valproic acid improves glucose homeostasis by increasing beta-cell proliferation, function, and reducing its apoptosis through HDAC inhibition in juvenile diabetic rat. J. Biochem. Mol. Toxicol. 30, 438\u2013446. https:\/\/doi.org\/10.1002\/jbt.21807 (2016).","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"24851_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3389\/fendo.2017.00147","volume":"8","author":"A Rakitin","year":"2017","unstructured":"Rakitin, A. Does valproic acid have potential in the treatment of diabetes mellitus?. Front. Endocrinol. 8, 147. https:\/\/doi.org\/10.3389\/fendo.2017.00147 (2017).","journal-title":"Front. Endocrinol."},{"key":"24851_CR25","doi-asserted-by":"publisher","first-page":"9678098","DOI":"10.1155\/2019\/9678098","volume":"2019","author":"R Soria-Castro","year":"2019","unstructured":"Soria-Castro, R. et al. Exploring the drug repurposing versatility of valproic acid as a multifunctional regulator of innate and adaptive immune cells. J. Immunol. Res. 2019, 9678098. https:\/\/doi.org\/10.1155\/2019\/9678098 (2019).","journal-title":"J. Immunol. Res."},{"key":"24851_CR26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","volume":"34","author":"A Duenas-Gonzalez","year":"2008","unstructured":"Duenas-Gonzalez, A. et al. Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat. Rev. 34, 206\u2013222. https:\/\/doi.org\/10.1016\/j.ctrv.2007.11.003 (2008).","journal-title":"Cancer Treat. Rev."},{"key":"24851_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.yexcr.2015.06.003","volume":"337","author":"Y Zhai","year":"2015","unstructured":"Zhai, Y. et al. Histone deacetylase inhibitor valproic acid promotes the induction of pluripotency in mouse fibroblasts by suppressing reprogramming-induced senescence stress. Exp. Cell Res. 337, 61\u201367. https:\/\/doi.org\/10.1016\/j.yexcr.2015.06.003 (2015).","journal-title":"Exp. Cell Res."},{"key":"24851_CR28","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1158\/1535-7163.mct-05-0184","volume":"4","author":"XN Li","year":"2005","unstructured":"Li, X. N. et al. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol. Cancer Ther. 4, 1912\u20131922. https:\/\/doi.org\/10.1158\/1535-7163.mct-05-0184 (2005).","journal-title":"Mol. Cancer Ther."},{"key":"24851_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4149\/neo_2011_01_35","volume":"58","author":"K Elknerova","year":"2011","unstructured":"Elknerova, K. et al. Epigenetic modulation of gene expression of human leukemia cell lines: Induction of cell death and senescence. Neoplasma 58, 35\u201344. https:\/\/doi.org\/10.4149\/neo_2011_01_35 (2011).","journal-title":"Neoplasma"},{"key":"24851_CR30","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.2337\/db14-1820","volume":"64","author":"AK Palmer","year":"2015","unstructured":"Palmer, A. K. et al. Cellular senescence in type 2 diabetes: A therapeutic opportunity. Diabetes 64, 2289\u20132298. https:\/\/doi.org\/10.2337\/db14-1820 (2015).","journal-title":"Diabetes"},{"key":"24851_CR31","doi-asserted-by":"publisher","first-page":"F1563","DOI":"10.1152\/ajprenal.90302.2008","volume":"295","author":"D Verzola","year":"2008","unstructured":"Verzola, D. et al. Accelerated senescence in the kidneys of patients with type 2 diabetic nephropathy. Am. J. Physiol. Renal Physiol. 295, F1563-1573. https:\/\/doi.org\/10.1152\/ajprenal.90302.2008 (2008).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"24851_CR32","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jdiacomp.2014.05.010","volume":"28","author":"K Kitada","year":"2014","unstructured":"Kitada, K. et al. Hyperglycemia causes cellular senescence via a SGLT2- and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy. J. Diabetes Complic. 28, 604\u2013611. https:\/\/doi.org\/10.1016\/j.jdiacomp.2014.05.010 (2014).","journal-title":"J. Diabetes Complic."},{"key":"24851_CR33","doi-asserted-by":"publisher","first-page":"C374","DOI":"10.1152\/ajpcell.00096.2010","volume":"299","author":"J Satriano","year":"2010","unstructured":"Satriano, J. et al. Transition of kidney tubule cells to a senescent phenotype in early experimental diabetes. Am. J. Physiol. Cell Physiol. 299, C374\u2013C380. https:\/\/doi.org\/10.1152\/ajpcell.00096.2010 (2010).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"24851_CR34","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41574-018-0059-4","volume":"14","author":"C Franceschi","year":"2018","unstructured":"Franceschi, C., Garagnani, P., Parini, P., Giuliani, C. & Santoro, A. Inflammaging: A new immune\u2013metabolic viewpoint for age-related diseases. Nat. Rev. Endocrinol. 14, 576\u2013590. https:\/\/doi.org\/10.1038\/s41574-018-0059-4 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"key":"24851_CR35","doi-asserted-by":"publisher","first-page":"1810327","DOI":"10.1155\/2016\/1810327","volume":"2016","author":"F Prattichizzo","year":"2016","unstructured":"Prattichizzo, F. et al. \u201cInflammaging\u201d as a druggable target: A senescence-associated secretory phenotype\u2014centered view of type 2 diabetes. Oxid. Med. Cell. Longev. 2016, 1810327. https:\/\/doi.org\/10.1155\/2016\/1810327 (2016).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"24851_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00734","author":"R Franzin","year":"2020","unstructured":"Franzin, R. et al. Inflammaging and complement system: A link between acute kidney injury and chronic graft damage. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.00734 (2020).","journal-title":"Front. Immunol."},{"key":"24851_CR37","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2021.0125","author":"SM Tan","year":"2022","unstructured":"Tan, S. M., Snelson, M., \u00d8stergaard, J. A. & Coughlan, M. T. The complement pathway: New insights into immunometabolic signaling in diabetic kidney disease. Antioxid. Redox Signal. https:\/\/doi.org\/10.1089\/ars.2021.0125 (2022).","journal-title":"Antioxid. Redox Signal."},{"key":"24851_CR38","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41581-019-0234-4","volume":"16","author":"SCW Tang","year":"2020","unstructured":"Tang, S. C. W. & Yiu, W. H. Innate immunity in diabetic kidney disease. Nat. Rev. Nephrol. 16, 206\u2013222. https:\/\/doi.org\/10.1038\/s41581-019-0234-4 (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"24851_CR39","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3892\/etm.2021.10548","volume":"22","author":"Y Wen","year":"2021","unstructured":"Wen, Y., Shen, F. & Wu, H. Role of C5a and C5aR in doxorubicin-induced cardiomyocyte senescence. Exp. Ther. Med. 22, 1114. https:\/\/doi.org\/10.3892\/etm.2021.10548 (2021).","journal-title":"Exp. Ther. Med."},{"key":"24851_CR40","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1096\/fj.10-154765","volume":"24","author":"MC Hu","year":"2010","unstructured":"Hu, M. C. et al. Klotho: A novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J. 24, 3438\u20133450. https:\/\/doi.org\/10.1096\/fj.10-154765 (2010).","journal-title":"FASEB J."},{"key":"24851_CR41","doi-asserted-by":"publisher","first-page":"162","DOI":"10.2215\/CJN.02840320","volume":"16","author":"JA Neyra","year":"2020","unstructured":"Neyra, J. A., Hu, M. C. & Moe, O. W. Klotho in clinical nephrology: Diagnostic and therapeutic implications. Clin. J. Am. Soc. Nephrol. CJASN 16, 162\u2013176. https:\/\/doi.org\/10.2215\/CJN.02840320 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"24851_CR42","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.jdiacomp.2016.03.006","volume":"30","author":"SS Kim","year":"2016","unstructured":"Kim, S. S. et al. Decreased plasma \u03b1-Klotho predict progression of nephropathy with type 2 diabetic patients. J. Diabetes Complic. 30, 887\u2013892. https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.03.006 (2016).","journal-title":"J. Diabetes Complic."},{"key":"24851_CR43","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1515\/bc.2008.028","volume":"389","author":"M Kuro-o","year":"2008","unstructured":"Kuro-o, M. Klotho as a regulator of oxidative stress and senescence. Biol. Chem. 389, 233\u2013241. https:\/\/doi.org\/10.1515\/bc.2008.028 (2008).","journal-title":"Biol. Chem."},{"key":"24851_CR44","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/ajt.13415","volume":"16","author":"G Castellano","year":"2016","unstructured":"Castellano, G. et al. Complement modulation of anti-aging factor klotho in ischemia\/reperfusion injury and delayed graft function. Am. J. Transplant. 16, 325\u2013333. https:\/\/doi.org\/10.1111\/ajt.13415 (2016).","journal-title":"Am. J. Transplant."},{"key":"24851_CR45","doi-asserted-by":"publisher","first-page":"5062","DOI":"10.1038\/s41467-022-32477-9","volume":"13","author":"MDM Al-Dabet","year":"2022","unstructured":"Al-Dabet, M. D. M. et al. Reversal of the renal hyperglycemic memory in diabetic kidney disease by targeting sustained tubular p21 expression. Nat. Commun. 13, 5062. https:\/\/doi.org\/10.1038\/s41467-022-32477-9 (2022).","journal-title":"Nat. Commun."},{"key":"24851_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114156","volume":"180","author":"XX Li","year":"2020","unstructured":"Li, X. X. et al. Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function. Biochem. Pharmacol. 180, 114156. https:\/\/doi.org\/10.1016\/j.bcp.2020.114156 (2020).","journal-title":"Biochem. Pharmacol."},{"key":"24851_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069193","volume":"8","author":"SM Tan","year":"2013","unstructured":"Tan, S. M. et al. The modified selenenyl amide, M-hydroxy ebselen, attenuates diabetic nephropathy and diabetes-associated atherosclerosis in ApoE\/GPx1 double knockout mice. PLoS ONE 8, e69193. https:\/\/doi.org\/10.1371\/journal.pone.0069193 (2013).","journal-title":"PLoS ONE"},{"key":"24851_CR48","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8 (2014).","journal-title":"Genome Biol."},{"key":"24851_CR49","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s12864-020-06856-9","volume":"21","author":"A Kaspi","year":"2020","unstructured":"Kaspi, A. & Ziemann, M. mitch: Multi-contrast pathway enrichment for multi-omics and single-cell profiling data. BMC Genom. 21, 447. https:\/\/doi.org\/10.1186\/s12864-020-06856-9 (2020).","journal-title":"BMC Genom."},{"key":"24851_CR50","doi-asserted-by":"publisher","first-page":"D498","DOI":"10.1093\/nar\/gkz1031","volume":"48","author":"B Jassal","year":"2019","unstructured":"Jassal, B. et al. The reactome pathway knowledgebase. Nucleic Acids Res. 48, D498\u2013D503. https:\/\/doi.org\/10.1093\/nar\/gkz1031 (2019).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24851-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24851-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24851-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T07:11:35Z","timestamp":1669360295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24851-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["24851"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-24851-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"assertion":[{"value":"17 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20278"}}